Risk factors and prognostic factors in patients with double primary cancer: Epithelial ovarian cancer and breast cancer

Background and objective: The most important known risk factor for ovarian cancer is the BRCA1-2 mutation, which is clinically often manifested through a positive family history of cancer of the breast and/or ovary. Whether other risk factors and prognostic factors in women with a positive family history of cancer of the breast and/or ovary and/or with BRCA1-2 mutation are important remains to be elucidated. Recent studies have shown that in the double primary breast and ovarian cancer (DPBOC), BRCA1-2 mutation is present in at least 86% of cases. Therefore, the group of patients with DPBOC, especially with epithelial ovarian cancer and breast cancer, is the most suitable for such an analysis. The aim of this study was to verify the hypothesis that, in this group, some other risk factors, in addition to a specific family history of cancer, as well as unfavourable pathomorphological prognostic factors, are more expressed than in a control group of patients with sporadic epithelial ovarian cancer only.

Methods: We compared the study group of 31 patients with DPBOC (epithelial ovarian cancer) to a control group of 62 patients with a single, sporadic epithelial ovarian cancer and negative specific family history. The data were obtained from the Cancer Registry of Slovenia and from clinical records. For every patient, we filled-in a protocol and analysed the data, comparing other risk factors in addition to specific family history and prognostic, clinical, and pathomorphological factors. Statistical analysis was performed using descriptive statistics, chi-square test and t-test. Multivariate analysis was also planned, but the necessary conditions were not met.

Results: In the study group, we found a higher percentage of positive non-specific family histories than in the control group, but the difference was not statistically significant. No difference in procreative risk factors was observed between the groups. There was a higher percentage of borderline significance of women from the study group that developed ovarian cancer between 45 and 59 years of age. In the study group, ovarian cancer was significantly more often found at Stage I, although the groups did not differ in detection procedures. Also, we did not find any differences in the distribution of tumour grades or histologic tumour types.

Conclusion: The results did not confirm our hypothesis, yet they indicated some differences between the groups regarding the risk factors for ovarian cancer. Regarding the prognostic factors, we even found a significantly higher percentage of Stage I epithelial ovarian cancer in the study group, with no difference in the mode of detection. Considering the results that are not typical of BRCA-related cancer (what double primary cancer of the ovary and breast is supposed to be) and previous reports, we find it more likely that the patients with BRCA1-2 mutations represent only a subgroup within the group of patients with double primary breast and ovarian cancer.

Ovarian cancer; Breast cancer; BRCAl-2; Double primary cancer; Risk factors; Prognostic factors

[1] Ursic－Vrscaj M. et al.: "Prakticni napotki za genetsko svetovanJe rak jajcnikov in dojk". In: "16. onkoloski vikend. Doktrini zdravljenja bolnikov z malignimi limfomi in bolnic z rakom rodil Zbornik". Lasko, Slovensko zdravnisko drustvo, Kancerolosko zdruzenje, 2002, 109.

[2] Berry D.A., Parmigiani G., Sanchez J., Schildkraut J., Winer E "Probability of carrying a mutation of breast-ovarian cancer gene BRCAI based on family history". J. Nat. Cancer I., 1997, 89, 227.

[3] Shih H.A., Nathanson K.L., Seal S. et al.: "BRCAJ and BRCA2 mutations in breast cancer families with multiple primary cancers". Clin. Cancer Res., 2000, 6, 4259.

[4] Schorge J.O., Mahoney N.M., Miller D.S. et al.: "Germlrne BRCAl-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer". Gynecol. Oneal., 2001, 83, 383.

[5] Frank T.S.: "Laboratory determination of hereditary susceptibility to breast and ovarian cancer". Arch. Pathol. Lab. Med., 1999, 123, 1023.

[6] Ang P., Garber J.E.: "Genetic suscept加lity for breast cancer - risk assessment and counseling". Semin. Oneal., 2001, 4, 419.

[7] Berchuck A., Schildkraut J.M., Marks J.R., Futreal P.A.: "Managmg hereditary ovarian cancer risk". Cancer (suppl.), 1999, 86, 2517.

[8] Jernstrom H., Lerman C., Ghadirian P. et al.: "Pregnancy and risk of early breast cancer in carriers of BRCAl and BRCA 2". Lancet, 1999, 354, 1846.

[9] Narod S.A., Goldgar D., Cannon-Albright L. et al.: "Risk modifiers in carriers of BRCAJ mutations". Int. J Cancer, 1995, 64, 394.

[10] Becher H., Schmidt S., Chang-Claude J.: "Reproductive factors and familial predisposition for breast cancer by age 50 years. A case-control-family study for assesment of the main effects and possible gene-environment interaction". Int. J. Epidemiol., 2003, 32, 38.

[11] Rebbeck T.R.: "Inherited predisposition and breast cancer: modifiers of BRCAl/2-associated breast cancer risk". Environ. Mol Mutagen., 2002, 39, 228.

[12] Modan B., Hartge P., Hirsh-Yechezkel G. et al.: "Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCAI or BRCA2 mutation". N. Engl. J. Med., 2001, 345, 235.

[13] Antoniou A., Pharoah PD., Narod S. et al.: "Average risks of breast and ovarian cancer associated with BRCAI or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies". Am. J. Hum. Genet., 2003, 72, 1117.

[14] Narod S.A.: " Modifiers of risk of hereditary breast and ovarian cancer". Nat. Rev. Cancer, 2002, 2, 113.

[15] Fisher D.E.: " T he p53 tumor suppressor: Critical regulator of life & death in cancer". Apoptosis, 2001, 6, 7.

[16] Pierce L.J., Strawderman M., Marod SA et al.: " Effect of rad10- therapy after breast-conserving treatment in women with cancer and germline BRCAl-2 mutations". J. Clin. Oneal., 2000, 18, 3360.

[17] Rubin S.C., Benjamin I., Behbakht K. et al.: "Clinical and pathological features of ovarian cancer with germ-line mutations of BRCAI". N. Engl. J. Med., 1996, 335, 1414.

[18] Johannsson O.T., ldvall I., Anderson C. et al.: "Tumour biological features of BRCAl-induced breast and ovarian cancer". Eur. J. Cancer, 1997, 33, 362.

[19] Suris-Swartz P.J., Schildkraut J.M., Vine M.F., Hertz-Picciotto I "Age at diagnosis and multiple primary cancers of the breast and ovary." Breast Cancer Res. Treat., 1996, 41, 21.

[20] Fishman A., Aviram R., Beyth Y., Bernheim J., Altaras M.: "A second primary malignancy in a cohort of patients with epithelial ovarian cancer - characteristics of diagnosis". Eur. J. Gynaecol. Oneal., 1998, 19, 280.

[21] Fishman A., Dekel E., Chetrit A. et al.: "Patients with double primary tumors in the breast and ovary - clinical characteristics and BRCAl-2 mutations status". Gynecol. Oneal., 2000, 79, 74.

[22] Petrij-Bosch A., Peelen T., van Vliet M. et al.: "BRCAl genomic deletions are major founder mutations in Dutch breast cancer patients". Nat. Genet., 1997, 17, 341 (erratum published 17,503).

[23] Bergfeldt K., Nilsson B., Einhorn S., Hall P.: "Breast cancer risk in women with a primary ovarian cancer - a case-control study" Eur. J. Cancer, 2001, 37, 2229.